Under the licensing pact, the new company will take over the development and commercialization of Lilly‘s severe sepsis treatment, Xigris (drotrecogin alfa (activated)), in the US.
Additionally, BioCritica will also receive the rights to acquire several critical care compounds currently in pre-clinical development at Lilly.
The licensing pact also comprises a supply agreement, a services agreement and an option for BioCritica to acquire the development and commercialization rights to Xigris outside the US at a later date.
In return, Lilly is eligible to get royalties on future US sales of Xigris and will also receive an equity stake in BioCritica.
Lilly president, chairman and CEO John Lechleiter said the collaboration between Lilly and BioCritica will benefit both companies, as well as the patients they serve and the Indianapolis community in which they operate.
"We are confident that BioCritica will help realize the full potential for Xigris, while working to develop new critical care medicines," Lechleiter said.